Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof,

wherein

L represents —C(═O)— or —S(═O) m — and m represents 1 or 2;

either

R 1 represents C 1-6 alkyl, C 2- 6 alkenyl, C 2-6 alkynyl, halogenC 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl, C 1-6 alkylcarbonylC 1-6 alkyl, C 1-6 alkoxycarbonylC 1-6 alkyl, hydroxyC 1-6 alkyl, aminoC 1-6 alkyl, C 1-4 alkylaminoC 1-6 alkyl, diC 1-4 alkylaminoC 1-6 alkyl, aminocarbonylC 1-6 alkyl, C 1-4 alkylaminocarbonylC 1-6 alkyl, diC 1-4 alkylaminocarbonylC 1-6 alkyl, C 3-8 cycloalkylC 0-6 alkyl, phenylC 0-6 alkyl, heteroarylC 0-6 alkyl wherein the heteroaryl moiety is a 5- or 6- membered aromatic ring which comprises 1, 2, 3 or 4 heteroatoms individually selected from N, O and S, heterocyclylC 0-6 alkyl wherein the heterocyclyl moiety is a 5- or 6- membered non-aromatic ring which comprises 1, 2 or 3 heteroatoms individually selected from N, O and S, or —CR 7 R 8 wherein R 7 represents phenylC 0-5 alkyl and R 8 represents diC 1-2 alkylaminoC 1-4 alkyl, and wherein any of said cycloalkyl, phenyl, heteroaryl and heterocyclyl moieties are optionally substituted by 1, 2, 3, 4 or 5 substituents, which may be the same or different, selected from R 9,

R 2 represents hydrogen or methyl, or

R 1 and R 2 , together with the nitrogen atom to which they are attached, form a 5- or 6-membered non-aromatic heterocyclic ring which optionally comprises one additional heteroatom ring member selected from N and O and wherein said heterocyclic ring is optionally substituted by 1, 2, 3, 4 or 5 substituents, which may be the same or different, selected from R 9 ;

R 3 and R 4 independently represent hydrogen or methyl;

n represents 0 or 1;

R 5 and R 6 independently represent hydrogen, halogen, methyl or methoxy;

R 9 represents cyano, amino, halogen, hydroxy, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, halogenC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylamino, diC 1-4 alkylamino, C 1-4 alkylcarbonyl, C 1-4 alkoxycarbonyl, aminocarbonyl, C 1-4 alkylaminocarbonyl, diC 1-4 alkylaminocarbonyl, or C 1-4 alkoxycarbonylamino.

2. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein L represents —C(═O)—.

3. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 represents C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogenC 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl, C 1-6 alkylcarbonylC 1-6 alkyl, C 1-6 alkoxycarbonylC 1-6 alkyl, hydroxyC 1-6 alkyl, aminoC 1-6 alkyl, C 1-4 alkylaminoC 1-6 alkyl, diC 1-4 alkylaminoC 1-6 alkyl, aminocarbonylC 1-6 alkyl, C 1-4 alkylaminocarbonylC 1-6 alkyl, or diC 1-4 alkylaminocarbonylC 1-6 alkyl.

4. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 represents aminoC 1-6 alkyl, C 1-4 alkylaminoC 1-6 alkyl or diC 1-4 alkylaminoC 1-6 alkyl.

5. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 represents C 1-4 alkylaminoC 1-6 alkyl or diC 1-4 alkylaminoC 1-6 alkyl.

6. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 represents hydrogen.

7. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein n represents 0.

8. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 and R 6 individually represent hydrogen or fluoro.

9. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 and R 6 both represent hydrogen.

10. A compound of formula (I), or a pharmaceutically acceptable salt thereof,

wherein

L represents —C(═O)— or —S(═O) m —and m represents 1 or 2;

R 1 represents phenylC 0-6 alkylaminoC 1-6 alkyl or phenylC 0-6 alkylamino(C 1-4 alkyl)C 1-6 alkyl, and wherein any of said phenyl moieties are optionally substituted by 1, 2, 3, 4 or 5 substituents, which may be the same or different, selected from R 9 ,

R 2 represents hydrogen or methyl,

R 3 and R 4 independently represent hydrogen or methyl;

n represents 0 or 1;

R 5 and R 6 independently represent hydrogen, halogen, methyl or methoxy; and

R 9 represents cyano, amino, halogen, hydroxy, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, halogenC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylamino, diC 1-4 alkylamino, C 1-4 alkylcarbonyl, C 1-4 alkoxycarbonyl, aminocarbonyl, C 1-4 alkylaminocarbonyl, diC 1-4 alkylaminocarbonyl or C 1-4 alkoxycarbonylamino.

11. A compound according to claim 1 , which is selected from:

N,N-dimethyl-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-methyl-4-(5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)benzamide;

N-methyl-2[4-(5-trifluoromethyl-[ 1,2,4]oxadiazol-3-yl)-phenyl]-acetamide;

N,N-dimethyl-2-[4-(5-trifluoromethyl[1,2,4]oxadiazol-3-yl)-phenyl]-acetamide;

N-Isopropyl-2-[4-(5-trifluoromethyl-[1,2,4]oxadiazol-3-yl)-phenyl]-acetamide;

N-butyl-2-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)acetamide;

N-(2-methoxyethyl)-2-(4-(5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)phenyl)acetamide;

ethyl 2-(2-(4-(5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)phenyl)acetamido)acetate;

1-morpholino-2-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3 -yl)phenyl)ethanone;

1-(4-methylpiperazin-1-yl)-2-(4-(5 -(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)phenyl)ethanone;

N-methoxy-N-methyl-2-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)acetamide;

N-ethyl-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(2-hydroxyethyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-ethyl-N-methyl-4-(5-(trifluoromethyl)-4-oxadiazol-3-yl)benzamide;

N-(2-hydroxyethyl)-N-methyl-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(2-methoxyethyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(3-hydroxypropyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(2-methoxyethyl)-N-methyl-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-cyclopropyl-4-(5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)benzamide;

N-isopropyl-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(3-methoxypropyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(2-fluoroethyl)-4-(5 -(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

pyrrolidin-1-yl(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)methanone;

N-isopropyl-N-methyl-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-cyclobutyl-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(cyclopropylmethyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-isobutyl-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3 -yl)benzamide;

(R)-N-(1-hydroxypropan-2yl)-4(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-cyclopentyl-4-(5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)benzamide;

N-(pentan-3-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(2-(dimethylamino)ethyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

morpholino(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)methanone;

piperidin-1-yl(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)methanone;

N-cyclohexyl-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-phenyl-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

(4-methylpiperazin- 1-yl)(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)methanone;

N-(2-(dimethylamino)ethyl)-N-methyl-4-(5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)benzamide;

N-(1-methylpiperidin-4-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

(4-(dimethylamino)piperidin- 1-yl)(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) phenyl)methanone;

N-(3-(1H-imidazol- 1-yl)propyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(4-(dimethylamino)phenyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-phenethyl-4-(5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)benzamide;

N-benzyl-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(pyridin-4-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(pyridin-3-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-((1-methylpiperidin-4-yl)methyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

(S)-N-(1-hydroxypropan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(2-(dimethylamino)propyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(2-(dimethylamino)-2-oxoethyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(1-(dimethylamino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

(3 -hydroxypyrrolidin- 1-yl)(4-(5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)phenyl)methanone;

tert-butyl 4-(4-(5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)benzoyl)piperazine- 1-carboxylate;

N-(1-hydroxybutan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(tetrahydro-2H-pyran-4-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(1-hydroxy-4-methylpentan-2-yl)-4-(5-(trifluoromethyl)-1, 2,4-oxadiazol-3-yl)benzamide;

4-[4-(5-trifluoromethyl-[1,2,4]oxadiazol-3-yl)-benzoylamino]-piperidine-1-carboxylic acid tert-butyl ester;

tert-butyl (2-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamido)cyclohexyl)carbamate;

N-(2-hydroxycyclohexyl)-4-(5(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

tert-butyl 3-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamido)piperidine- 1-carboxylate;

N-(2-(methylamino)-2-oxoethyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(1- acetylpiperidin-4-yl)-4-(5 -(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-4-(5-(trifluoromethyl)-1, 2,4-oxadiazol-3-yl)benzamide;

tert-butyl 3-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamido)pyrrolidine-1-carboxylate;

N-(2-methoxypyridin-4-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(2,6-dimethylpyridin-4-yl)-4-(5-(trifluoromethyl)-1,24-oxadiazol-3-yl)benzamide;

N-(2-(tert-butyl)pyridin-4-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(2-methylpyridin-4-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(2-fluoropyridin-4-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(2-hydroxypyridin-4-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(2-cyanopyridin-4-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)benzamide;

N-(2-chloropyridin-4-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(piperidin-4-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(2- aminocyclohexyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(piperidin-2-ylmethyl)-4-(5-(tifluoromethyl)-1,2,4-oxadiazol-3 -yl)benzamide;

N-(piperidin-3-yl)-4-(5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)benzamide;

N-(pyrrolidin-3-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

(R)-N-(1-(dimethylamino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

(S)-N-(1-(dimethylamino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

(S)-N-(1-(dimethylamino)-3-methylbutan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

(R)-N-(1-(dimethylamino)-3-methylbutan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(R)-N-(1-(dimethylamino)-4-methylpentan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(R)-N-(pyrrolidin-3-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3 -yl)benzamide;

(S)-N-(pyrrolidin-3-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

(R)-N-(1-(dimethylamino)propan-2-yl)-2-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(R)-N-(1-(dimethylamino)-3-methylbutan-2-yl)-2-fluoro-4-(5 -(trifluoromethyl)-1,2,4-oxadiazol-3 -yl) benzamide;

N-(2,6-dimethylpyridin-4-yl)-2-fluoro-4-(5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)benzamide;

2-fluoro-N- (1-hydroxypropan-2-yl)-4-(5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl) benzamide;

(R)-N-(1-(dimethylamino)-3-phenylpropan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(S)-N-(1-(dimethylamino)-3-phenylpropan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

N-(1 -(dimethylamino)propan-2-yl)-N-methyl-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(R)-2-fluoro-N-(pyrrolidin-3-yl)-4-(5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl)benzamide;

N-phenyl-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzenesulfonamide;

N-benzyl-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3 -yl)benzenesulfonamide;

N-(2-(dimethylamino)ethyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzenesulfonamide;

N-(2-(dimethylamino)ethyl)-N-methyl-4-(5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl) benzenesulfonamide;

N-(pyridin-3-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3 -yl)benzenesulfonamide;

N-(cyclohexylmethyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzenesulfonamide; and

(R)-N-(pynolidin-3-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzenesulfonamide;

or a pharmaceutically acceptable salt thereof.

12. A compound according to claim 1 , which is selected from:

N-o-tolyl-4-(5-trifluoromethyl[1,2,4]oxadiazol-3 -yl)-benzenesulfonamide;

N-(2-chlorophenyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzenesulfonamide;

N-m-tolyl-4(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzenesulfonamide;

N-(3-fluorophenyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzenesulfonamide;

N-(3-chlorophenyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzenesulfonamide;

N-p-tolyl-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzenesulfonamide;

N-(4-fluorophenyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzenesulfonamide;

N-(4-chlorophenyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzenesulfonamide;

N-(2-fluorophenyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzenesulfonamide;

N-(3-(dimethylamino)propyl)-N-methyl-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzenesulfonamide;

N-(3-(dimethylamino)propyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzenesulfonamide;

N,N-dimethyl-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzenesulfonamide;

N-((1-methylpyrrolidin-3-yl)methyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzenesulfonamide;

N-(3-hydroxypropyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzenesulfonamide;

(S)-N-(1-(dimethylamino)-3-phenylpropan-2-yl)-2-fluoro-4-(5 -(trifluoromethyl)-1,2,4-oxadiazol -3-yl)benzamide;

(R)-N-(1-(dimethylamino)-3-phenylpropan-2-yl)-2-fluoro-4-(5 -(trifluoromethyl)-1,2,4-oxadiazol -3-yl)benzamide;

N-(1-(dimethylamino)-2-methylpropan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

N-(1-(dimethylamino)-2-methylpropan-2-yl)-2-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

N-(1-(diethylamino)propan-2-yl)-2-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

N-(2-(dimethylamino)propyl)-2-fluoro-4-(5-(trifluoromethyl)-1, 2,4-oxadiazol-3-yl)benzamide;

N-(1-(diethylamino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

(R)-N-(1-(dimethylamino)propan-2-yl)-2,6-difluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(R)-2-chloro-N-(1-(dimethylamino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(R)-N-(1-(diethylamino)propan-2-yl)-2-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(S)-N-(1-(diethylamino)propan-2-yl)-2-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(R)-2-fluoro-N-(1-(pyrrolidin- 1-yl)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(R)-2-fluoro-N-(1-(piperidin-1-yl)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3 -yl) benzamide;

(R)-N-(1-(pyrrolidin-1-yl)propan-2-yl)-4-(5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)benzarnide;

(R)-N-(1-(piperidin-1-yl)propan-2-yl)-4-(5-(trifluoromethyl)- 1,2,4-oxadiazol-3yl)benzamide;

(R)-N-(1-(diethylamino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

(S)-N-(1-(diethylamino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3 -yl)benzamide;

(R)-N-(1-(diethylamino)-3-methylbutan-2yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(R)-N-(1-(diethylamino)-3-methylbutan-2yl(-2-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(R)-N-(1-(ethyl(methyl)amino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(R)-N-(1-(dipropylamino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

(R)-N-(1-(isopropyl(methyl)amino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(R)-N-(1-(methyl(propyl)amino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(R)-N-(1-(ethyl(methyl)amino)propan-2-yl)-2-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(R)-N-(1-(dipropylamino)propan-2-yl)-2-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(R)-2-fluoro-N-(1-(isopropyl(methyl)amino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(R)-2-fluoro-N-(1-(methyl(propyl)amino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

N-(1-(dimethylamino)propan-2-yl)-2-fluoro-N-methyl-4-(5-(trifluoromethyl)-1,2, 4-oxadiazol-3-yl) benzamide;

(R)-N-(1-(ethyl(propyl)amino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(R)-N-(1-(ethyl(propyl)amino)propan-2-yl)-2-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(R)-N-(1-morpholinopropan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

(R)-2-fluoro-N-(1-morpholinopropan-2-yl)-4(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

N-(1-methylpiperidin-3-yl)-4-(5-(trifluoromethyl)-1, 4-oxadiazol-3-yl)benzamide;

(R)-N-(1-(butyl(methyl)amino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(R)-N-(1-(butyl(methyl)amino)propan-2-yl)-2-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide;

(R)-N-(1-(ethyl(isopropyl)amino)propan-2-yl)-2-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

(R)-N-(1-methylpyrrolidin-3-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3 -yl)benzamide;

(R)-N-(1-methylpiperidin-3-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

N-(2-(diethylamino)ethyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide; and

N-(2-(methylamino)ethyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

or a pharmaceutically acceptable salt thereof.

13. A compound selected from:

(4-phenylpiperazin-1-yl)(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)methanone;

(4-benzylpiperidin-1-yl)(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)methanone;

N-(4-(morpholinomethyl)benzyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide;

(R)-N-(1-(benzyl(methyl)amino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl) benzamide; and

N-(2-(phenylamino)ethyl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, as active pharmaceutical ingredient in association with at least one pharmaceutically acceptable carrier or diluent.

15. A method for the treatment of muscle atrophy, in a subject in need of such treatment, which method comprises administering to such subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

16. A method for the treatment of Huntington's disease, metabolic syndrome or diabetes, in a subject having Huntington's disease, metabolic syndrome or diabetes, which method comprises administering to such subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical combination comprising a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a second drug substance, for simultaneous or sequential administration.